HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinations

Gene Therapy

Volumn 9, Issue 13, 2002, Pages 879-888

  Mukai, K ^a   Yasutomi, Y ^a   Watanabe, M ^a   Kenjo, A ^b   Aota, T ^a   Wang, L ^a   Nishikawa, H ^a   Ishihara, M ^a   Fujita, T ^b   Kuribayashi, K ^a   Shiku, H ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

c erbB 2 HER2 neu; CD8+ T cells; CTL; DNA vaccine

Indexed keywords

AMINO ACID; CD8 ANTIGEN; DNA VACCINE; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; MEMBRANE ANTIGEN; ONCOPROTEIN; PROTEIN P63; TETRAMER;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE DELIVERY SYSTEM; INTERFERON PRODUCTION; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE NEU; PLASMID; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE THERAPY; GENES, ERBB-2; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; VACCINES, DNA;

MAMMALIA; VECTORS;

EID: 0036295892     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301707     Document Type: Article

References (43)

1. DNA vaccines: Immunology, application, and optimization
2. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses
3. DNA-mediated immunization to hepatitis B surface antigen: Longevity of primary response and effect of boost
4. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine
5. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
6. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
7. Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization
8. + T-cell responses induced by DNA immunization
9. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts
10. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas
11. + cytotoxic T lymphocytes
12. d-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals
13. + T-helper and a T-killer cell
14. CD4 T cells and their role in antitumor immune responses
15. + T cells in the antitumor immune response
16. Epitope affinity for MHC class I determines helper requirement for CTL priming
17. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors
18. DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice
19. DNA vaccination against rat HER-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
20. neu to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice
21. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice
22. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
23. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination
24. + T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity
25. + T cells in antitumor immunity
26. d mice that reject syngeneic tumors
27. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization
28. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
29. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
30. + T cell adoptive immunotherapy
31. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases
32. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: Description of a unique antigen on BALB/c Meth A sarcoma
33. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity
34. Selection of highly transfectable variant from mouse mastocytoma P815
35. Efficient selection for high-expression transfectants with a novel eukaryotic vector
36. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
37. A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells
38. Phenotypic analysis of antigen-specific T lymphocytes
39. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
40. + T cells in vivo
41. Bone marrow-derived dendritic cells incorporate and process hydrophobized polysaccharide/oncoprotein complex as antigen presenting cells
42. A rapid method for the isolation of functional thymus-derived murine lymphocytes
43. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity